Safety evidence announced at the ESC Congress 2026 by Isomab has reinforced the potential of a new class of therapies designed to promote blood vessel growth as a disease-modifying approach for coronary artery disease (CAD).  

The systematic review of clinical trial data evaluating growth factor approaches, spanning more than two decades, found no evidence of the hypothesised safety concerns associated with directly stimulating blood vessel growth. 

Isomab is set to advance its lead candidate ISM-001 towards first-in-human trials in patients with chronic angina who are refractory to treatment, a severe and common manifestation of CAD.  

Unlike growth factor approaches that directly stimulate blood vessel growth, ISM-001 takes a fundamentally different approach: it is designed to selectively target VEGF-A165b, an inhibitor on angiogenesis – the process by which new blood vessels form from pre-existing vessels.  

The systematic review analysed 11 clinical studies evaluating growth factor approaches between 2002 and 2024 across 636 patients with angina or peripheral artery disease, with follow-up periods ranging from two to 12 years. 

The analysis found no evidence of additional long-term safety risks for proangiogenic interventions, including VEGF‑A isoforms, compared with placebo or age-matched populations.  Mean malignancy incidence was similar for pro-angiogenic interventions and placebo and was below the age‑matched population rate. 

“These findings represent an important step forward for the field of therapeutic angiogenesis. They resolve safety questions that have clouded the perception of an entire class of treatments and give us a strong foundation as we advance ISM-001 towards first-in-human studies. Rather than forcing blood vessel growth, ISM-001 takes a fundamentally different approach by removing the overactive brake on this natural process caused by cardiovascular disease, allowing the heart’s own backup system to kick in and help restore blood flow where it’s needed,” said Professor David Bates, Isomab Chief Scientific Officer and study author.